FATE THERAPEUTICS INC Proceeds from Maturities, Prepayments and Calls of Short-term Investments
FATE THERAPEUTICS INC (FATE) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $64.05 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2019-11-05
- FATE THERAPEUTICS INC proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2019-09-30 was $37.55M, a 168.21% increase year-over-year.
- FATE THERAPEUTICS INC proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2019-06-30 was $16.00M, a 14.29% increase year-over-year.
- FATE THERAPEUTICS INC proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2019-03-31 was $10.50M, a 12.50% decline year-over-year.
- FATE THERAPEUTICS INC proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2018-12-31 was $17.50M, a 25.00% increase year-over-year.
- FATE THERAPEUTICS INC proceeds from maturities, prepayments and calls of short-term investments for fiscal 2018 was $57.50M, a 82.54% increase from fiscal 2017.
- FATE THERAPEUTICS INC proceeds from maturities, prepayments and calls of short-term investments for fiscal 2017 was $31.50M, a 96.88% increase from fiscal 2016.
- FATE THERAPEUTICS INC proceeds from maturities, prepayments and calls of short-term investments for fiscal 2016 was $16.00M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2019-09-30 | $37.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $53.55M derived: sum of 2 quarters · filed 2019-11-05 | $64.05M 10-Q · filed 2019-11-05 | $81.55M derived: sum of 4 quarters · filed 2019-11-05 |
| 2019-06-30 | $16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $26.50M 10-Q · filed 2019-08-06 | $44.00M derived: sum of 3 quarters · filed 2019-08-06 | $58.00M derived: sum of 4 quarters · filed 2019-11-05 |
| 2019-03-31 | $10.50M 10-Q · filed 2019-05-07 | $28.00M derived: sum of 2 quarters · filed 2019-05-07 | $42.00M derived: sum of 3 quarters · filed 2019-11-05 | $56.00M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-12-31 | $17.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $31.50M derived: sum of 2 quarters · filed 2019-11-05 | $45.50M derived: sum of 3 quarters · filed 2019-11-05 | $57.50M 10-K · filed 2019-03-05 |
| 2018-09-30 | $14.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $28.00M derived: sum of 2 quarters · filed 2019-11-05 | $40.00M 10-Q · filed 2019-11-05 | $54.00M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $14.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $26.00M 10-Q · filed 2019-08-06 | $40.00M derived: sum of 3 quarters · filed 2019-08-06 | $54.00M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $12.00M 10-Q · filed 2019-05-07 | $26.00M derived: sum of 2 quarters · filed 2019-05-07 | $40.00M derived: sum of 3 quarters · filed 2019-05-07 | $41.75M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $28.00M derived: sum of 2 quarters · filed 2019-03-05 | $29.75M derived: sum of 3 quarters · filed 2019-03-05 | $31.50M 10-K · filed 2019-03-05 |
| 2017-09-30 | $14.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $15.75M derived: sum of 2 quarters · filed 2018-11-01 | $17.50M 10-Q · filed 2018-11-01 | $23.50M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $3.50M 10-Q · filed 2018-08-06 | $9.50M derived: sum of 3 quarters · filed 2019-03-05 | $13.50M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-03-31 | $1.75M 10-Q · filed 2018-05-10 | $7.75M derived: sum of 2 quarters · filed 2019-03-05 | $11.75M derived: sum of 3 quarters · filed 2019-03-05 | |
| 2016-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $10.00M derived: sum of 2 quarters · filed 2019-03-05 | $16.00M 10-K · filed 2019-03-05 | |
| 2016-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $10.00M 10-Q · filed 2017-11-01 | ||
| 2016-06-30 | $6.00M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |